Prognostic value of the levels of CTLA-4 and its ligand B7.2 in patients with colorectal cancer
https://doi.org/10.20538/1682-0363-2023-2-104-110
Abstract
Aim. To develop a computer program to determine the probability of colorectal cancer based on the assessment of the levels of CTLA-4 and its ligand B7.2.
Materials and methods. The study included 44 patients with colorectal cancer (CRC) and 25 patients with benign tumors of the colon. The control group consisted of 25 individuals who had been operated for colon injury. We determined the levels of CTLA-4 and B7.2 in the blood serum and in the supernatants of tumor tissue and lymph node homogenates using flow cytofluorometry.
Results. We found that the level of CTLA-4 in the blood serum increased by 2.77 times in CRC patients compared to the control group (p < 0.001). The concentration of CTLA-4 in the tumor tissue in patients with CRC was 2.34 times higher than in the control group (p = 0.007). The concentration of the B7.2 ligand in the blood serum of patients with CRC exceeded this parameter in the control group by 2.51 times (p = 0.002). The concentration of B7.2 in the tumor tissue of CRC patients was 1.68 times higher (p = 0.004) than in the control group. The analysis of the obtained data determined the parameters that have prognostic value in the structure of the diagnostic model. Using these parameters, we developed a computer program to determine the probability of CRC in the patient.
Conclusion. The data obtained demonstrate an increase in the levels of CTLA-4 and its ligand B7.2 in the serum and tumor tissue of patients with CRC.
About the Authors
A. V. Chetveryakov
Chita State Medical Academy
Russian Federation
Russian Federation
39a, Gorkogo Str., Chita, 672000
V. L. Tsepelev
Chita State Medical Academy
Russian Federation
Russian Federation
39a, Gorkogo Str., Chita, 672000
References
1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68(6):394–424. DOI: 10.3322/caac.21492.
2. Siegel R.L., Miller K.D., Fedewa S.A., Ahnen D.J., Meester R.G.S., Barzi A. et al. Colorectal cancer statistics. CA Cancer J. Clin. 2017;67(3):177–193. DOI: 10.3322/caac.21395.
3. Zhu Y., Hu Y., Kong X., Xiao Q., Pan Z., Zheng Z. et al. Cohort profile: The National Colorectal Cancer Cohort (NCRCC) study in China. BMJ Open. 2021;11(12):e051397. DOI: 10.1136/bmjopen-2021-051397.
4. Zhu S., Yi M., Wu Y., Dong B., Wu K., Zhu S. Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies. Exp. Hematol. Oncol. 2021;10(1):60. DOI: 10.1186/s40164-021-00252-z.
5. Eptaminitaki G.C., Wolff N., Stellas D., Sifakis K., Baritaki S. Long non-coding RNAs (lncRNAs) in response and resistance to cancer immunosurveillance and immunotherapy. Cells. 2021;10(12):3313. DOI: 10.3390/cells10123313.
6. Prakadan S.M., Alvarez-Breckenridge C.A., Markson S.C., Kim A.E., Klein R.H., Nayyar N. et al. Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases. Nat. Commun. 2021;12(1):5955. DOI: 10.1038/s41467-021-25860-5.
7. Feng Y., Liu L., Li J., Huang J., Xie J.H., Menard L. et al. Systematic characterization of the tumor microenvironment in Chinese patients with hepatocellular carcinoma highlights intratumoral B cells as a potential immunotherapy target. Oncol. Rep. 2022;47(2):38. DOI: 10.3892/or.2021.8249.
8. Yin J., Wang H., Hong Y., Ren A., Wang H., Liu L. et al. Identification of an at-risk subpopulation with high immune infiltration based on the peroxisome pathway and TIM3 in colorectal cancer. BMC Cancer. 2022;22(1):44. DOI: 10.1186/s12885-021-09085-9.
9. Sharma P., Allison J.P. The future of immune checkpoint therapy. Science. 2015;348(6230):56–61. DOI: 10.1126/science.aaa8172.
10. Shapoval A.I., Shapoval S.P., Shcherbakova N.S., Shcherbakov D.N. Immune control Molecules of the B7 family. Part 1. General characteristics and first representatives: b7- 1, b7-2, b7-h1, b7-h2 and b7-dc. Russian Journal of Bioorganic Chemistry. 2019;45(4):348–364. DOI: 10.1134/S1068162019040101.
11. Rowshanravan B., Halliday N., Sansom D.M. CTLA-4: a moving target in immunotherapy. Blood. 2018;131(1):58–67. DOI: 10.1182/blood-2017-06-741033.
12. Borrie A.E., Maleki Vareki S. T lymphocyte-based cancer immunotherapeutics. Int. Rev. Cell. Mol. Biol. 2018;341:201– 276. DOI: 10.1016/bs.ircmb.2018.05.010.
13. Общероссийский национальный союз «Ассоциация онкологов России». Злокачественные новообразования ободочной кишки и ректосигмоидного отдела. Клинические рекомендации. М., 2020:70.
14. Alshogran O.Y., Al-Delaimy W.K. Understanding of international committee of medical journal editor’s authorship criteria among faculty members of pharmacy and other health sciences in Jordan. J. Empir. Res. Hum. Res. Ethics. 2018;13(3):276–284. DOI: 10.1177/15562646187 64575.
15. Lang T.A., Altman D.G. Basic statistical reporting for articles published in biomedical journals: the “Statistical analyses and methods in the published literature” or the SAMPL guidelines. Int. J. Nurs. Stud. 2015;52(1):5–9. DOI: 10.1016/j.ijnurstu.2014.09.006.
16. Мудров В.А. Алгоритмы статистического анализа количественных признаков в биомедицинских исследованиях с помощью пакета программ SPSS. Забайкальский медицинский вестник. 2020;1:140–150. DOI: 10.52485/19986173_2020_1_140.
17. Мудров В.А. Алгоритмы статистического анализа качественных признаков в биомедицинских исследованиях с помощью пакета программ SPSS. Забайкальский медицинский вестник. 2020;1:151–163. DOI: 10.52485/19986173_2020_1_151.
18. Мудров В.А. Алгоритмы корреляционного анализа данных в биомедицинских исследованиях с помощью пакета программ SPSS. Забайкальский медицинский вестник. 2020;2:169–176. DOI: 10.52485/19986173_2020_2_169.
19. Четверяков А.В., Цепелев В.Л., Крюкова В.В., Мудров В.А. Программа для определения вероятности онкологической патологии толстого кишечника. ФГБОУ ВО ЧГМА МЗ РФ. URL: https://new.fips.ru/ofpstorage/Doc/PrEVM/RUNWPR/000/002/022/613/721/2022613721-00001/document.pdf.
20. Bagbudar S., Karanlik H., Cabioglu N., Bayram A., Ibis K., Aydin E. et al. Prognostic implications of immune infiltrates in the breast cancer microenvironment: the role of expressions of CTLA-4, PD-1, and LAG-3. Appl. Immunohistochem. Mol. Morphol. 2022;30(2):99–107. DOI: 10.1097/PAI.0000000000000978.
21. Guo X.J., Lu J.C., Zeng H.Y., Zhou R., Sun Q.M., Yang G.H. et al. CTLA-4 synergizes with PD1/PD-L1 in the inhibitory tumor microenvironment of intrahepatic cholangiocarcinoma. Front. Immunol. 2021;12:705378. DOI: 10.3389/fimmu.2021.705378.
Review
For citations:
Chetveryakov A.V., Tsepelev V.L. Prognostic value of the levels of CTLA-4 and its ligand B7.2 in patients with colorectal cancer. Bulletin of Siberian Medicine. 2023;22(2):104-110. https://doi.org/10.20538/1682-0363-2023-2-104-110
Views:
292
Email this article 